Remote Ischemic Preconditioning on Pulmonary Injury in Cardic Surgery
Launched by XUZHOU MEDICAL UNIVERSITY · Jan 7, 2017
Trial Information
Current as of June 04, 2025
Unknown status
Keywords
ClinConnect Summary
Remote ischemic preconditioning (RIPC) protocol will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood pressure cuff inflated to a pressure 200mmHg
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing heart surgery on cardiopulmonary bypass
- • 2. Patients aged 18 years to 80 years
- Exclusion Criteria:
- • 1. Inability to give informed consent
- • 2. Preoperative severe impairment of respiratory function (arterial oxygen tension (PaO2) \<60 mmHg or FEV1\<50% predicted)
- • 3. Prior receipt of chemotherapy or radiation therapy or immunotherapy
- • 4. left ventricular ejection fraction less than 30%
- • 5. preoperative use of inotropics or mechanical assist device
- • 6. Patients with significant hepatic dysfunction (Prothrombin\>2.0 ratio)
- • 7. Patients with known renal failure with a GFR\<30 mL/min/1.73 m2
- • 8. recent myocardial infarction (within 7 days)
- • 9. Systemic or local active infections (either clinically defined or suggested by evidence such as elevated C-reactive protein levels, leukocytosis, or a body temperature\>38℃)
- • 10. Significant peripheral arterial disease affecting the upper limbs
- • 11. surgeries: cardiac transplantation, concomitant carotid endarterectomy , previous heart surgery,, off-pump surgery, emergency surgery
About Xuzhou Medical University
Xuzhou Medical University is a leading institution in medical education and research, dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on scientific rigor and ethical standards, the university conducts a range of studies aimed at improving patient outcomes and contributing to the global body of medical knowledge. Leveraging its state-of-the-art facilities and a team of experienced researchers and clinicians, Xuzhou Medical University fosters collaboration across disciplines to address critical health challenges, ensuring the highest level of care and safety for trial participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xuzhou, Jiangsu, China
Patients applied
Trial Officials
Liu Su, M.D/Ph.D
Principal Investigator
The Affiliated Hospital of Xuzhou Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials